Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-306 in Hyperphosphatemia
NCT05764590Phase 2Completed
- Sponsor
- Alebund Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of EOS789 in hyperphosphatemia (2 arms), sponsored by Alebund Pharmaceuticals. Primary endpoint: Change in serum phosphorus from baseline at 12 weeks. Started Feb 2023; status: completed.
02
Drugs
EOS789
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT05764590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05764590.